References
- Al-Mohsen I, Hughes WT. (1998). Systemic antifungal therapy: Past, present and future. Ann Saudi Med 18:28–38
- Borecká-Melkusová S, Moran GP, Sullivan DJ, et al. (2009). The expression of genes involved in the ergosterol biosynthesis pathway in Candida albicans and Candida dubliniensis biofilms exposed to fluconazole. Mycoses 52:118–28
- Bruzual I, Riggle P, Hadley S, Kumamoto CA. (2007). Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole. J Antimicrob Chemother 59:441–50
- Cantón E, Pemán J, Gobernado M, et al. (2005). Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 49:1593–6
- Cavalheiro AS, Maboni G, de Azevedo MI, et al. (2009). In vitro activity of terbinafine combined with caspofungin and azoles against Pythium insidiosum. Antimicrob Agents Chemother 53:2136–8
- Espinel-Ingroff A. (2008). Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam Micol 25:101–6
- Ferahbas A, Koc AN, Uksal U, et al. (2006). Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther 13:332–6
- Geber A, Hitchcock CA, Swartz JE, et al. (1995). Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 39:2708–17
- Ghannoum M, Elewski B. (1999). Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immun 6:921–3
- Ghannoum MA, Rice LB. (1999). Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–17
- Khodavandi A, Alizadeh F, Harmal NS, et al. (2011). Expression analysis of SIR2 and SAPs1-4 gene expression in Candida albicans treated with allicin compared to fluconazole. Trop Biomed 28:589–98
- Lupetti A, Danesi R, Campa M, et al. (2002). Molecular basis of resistance to azole antifungals. Trends Mol Med 8:76–81
- Odds FC. (1996). Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents 6:145–7
- Park S, Perlin DS. (2005). Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 11:232–8
- Pasrija R, Krishnamurthy S, Prasad T, et al. (2005). Squalene epoxidase encoded by ERG1 affects morphogenesis and drug susceptibilities of Candida albicans. J Antimicrob Chemother 55:905–13
- Perea S, Gonzalez G, Fothergill AW, Rinaldi MG. (2002). In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 40:1831–3
- Rossie K, Guggenheimer J. (1997). Oral candidiasis: Clinical manifestation, diagnosis, and treatment. Pract Periodontics Aesthet Dent 9:635–41
- Scheid LA, Mario DAN, Kubiça TF, et al. (2012). In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and resistant strains of Candida dubliniensis. Braz J Infect Dis 16:78–81
- Spampinato C, Leonardi D. (2013). Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents. Biomed Res Int 2013:204237
- Yang YL. (2003). Virulence factors of Candida species. J Microbiol Immunol Infect 36:223–8